The Technical Analyst
Seattle Genetics Inc [SGEN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Seattle Genetics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.07% $228.74
America/New_York / 13 des 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 43 155 mill |
| EPS: | -4.00 |
| P/E: | -57.19 |
| Earnings Date: | Feb 12, 2024 |
| SharesOutstanding: | 188.66 mill |
| Avg Daily Volume: | 1.634 mill |
| RATING 2023-12-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -57.19 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -9.73x |
| Company: PE -57.19 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 227.32 - 230.16 ( +/- 0.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-14 | Baker Bros. Advisors Lp | Sell | 42 977 301 | Common Stock |
| 2023-12-14 | Baker Bros. Advisors Lp | Sell | 8 750 | Stock Options (right to buy) |
| 2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
| 2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
| 2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
| INSIDER POWER |
|---|
| -100.00 |
| Last 100 transactions |
| Buy: 0 | Sell: 44 783 214 |
Forecast:
01:40 - $224.96
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $228.74 (-0.07% ) |
| Volume | 19.39 mill |
| Avg. Vol. | 1.634 mill |
| % of Avg. Vol | 1 186.81 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SGEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Last 10 Buy Signals
Latest Press Releases
2023-12-14 07:39:00 - Press Release
Pfizer Completes Acquisition Of Seagen
New york--(business wire)--pfizer inc. (nyse: pfe) today announced the successful completion of its acquisition of seagen inc. (nasdaq: sgen), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. pfizer completed its acquisition of all outstanding common stock of seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “cancer remains a leading cause of death, and one in three people in the u.s. will rec.
2023-12-12 06:45:00 - Press Release
Pfizer Receives All Required Regulatory Approvals To Complete The Acquisition Of Seagen
New york--(business wire)--pfizer inc. (nyse: pfe) today announces that the waiting period under the hart-scott-rodino antitrust improvements act of 1976, as amended, expired december 11, 2023, with respect to pfizer's pending acquisition of seagen inc. (nasdaq: sgen). pfizer and seagen have now received all required regulatory approvals to complete the acquisition. pfizer expects to close the acquisition of seagen on december 14, 2023, subject to the satisfaction of other customary closing con.
2023-12-10 19:30:00 - Press Release
Adcetris® (brentuximab Vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma
Bothell, wash.--(business wire)-- #ash23--seagen inc. (nasdaq: sgen) today announced that clinically meaningful progression-free survival (pfs), a secondary endpoint, was observed in a phase 2 study evaluating the antibody-drug conjugate (adc) adcetris® (brentuximab vedotin) in combination with the pd-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (an+ad) as first-line treatment for early and advanced stage classical hodgkin lymphoma (chl). this is the first time 12-m.
2023-12-06 08:15:00 - Press Release
Tukysa® (tucatinib) In Combination With Antibody-drug Conjugate Ado-trastuzumab Emtansine Improves Progression-free Survival In Patients With Previously Treated Her2-positive Metastatic Breast Cancer
Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced data from the phase 3 her2climb-02 clinical trial of tukysa® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (kadcyla®). the combination showed a statistically significant improvement in progression-free survival (pfs), the study's primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (her2-positive) breast c.
2023-11-30 17:00:00 - Press Release
Fda Grants Priority Review For Supplemental Biologics License Application (sbla) Of Padcev® (enfortumab Vedotin-ejfv) With Keytruda® (pembrolizumab) For First-line Treatment Of Advanced Bladder Cancer
Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq: sgen) and astellas pharma inc. (tse:4503) today announced that on november 30, 2023 the u.s. food and drug administration (fda) accepted for priority review a supplemental biologics license application (sbla) for padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/muc), a form of bladder cancer that has.
Latest News
2024-04-13 10:00:00 - WSJ
Two Brothers, a Big Biotech Bet and an $8 Billion Payout
Investors in a hedge fund from Baker Bros. Advisors recently received one of the largest windfalls ever following Pfizer's purchase of Seagen.
2024-01-30 17:03:43 - Yahoo Finance
Pfizer CEO doubles down on 2024 guidance, talks Seagen buy
Pfizer (PFE) reported fourth-quarter earnings on Tuesday morning that beat. Wall Street expectations.
2023-12-21 13:05:16 - Seeking Alpha
5 Biotech Acquisition Targets To Accumulate In 2024
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.
2023-12-13 10:23:03 - Proactive Investors
Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen
Pfizer Inc (NYSE:PFE) said today that it is expecting $58.5 billion to $61.5 billion of sales in 2024 from Covid-19 vaccines, antiviral medicine Paxlovid and Seagen, with deal for the latter cancer drug company imminent. This is higher than its legacy 2024 guidance and slightly above the guidance it gave in October for 2023 sales.
2023-12-12 09:51:16 - Proactive Investors
Pfizer to close Seagen acquisition after donating cancer drug rights
Pfizer Inc (NYSE:PFE) announced on Tuesday that it will donate the rights of royalties from sales of cancer drug Bavencio to the American Association for Cancer Research (AACR) in order to address concerns from US antitrust regulators related to its pending $43-billion acquisition of Seagen Inc. The big US drugmaker said it now expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions. Pfizer noted the waiting period for the Federal Trade Commission to oppose the acquisition expired on Monday.
2023-12-12 07:06:06 - Reuters
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
Pfizer said on Tuesday it has agreed to donate the rights of royalties from sales of cancer drug Bavencio to address concerns from U.S. antitrust regulators related to its $43-billion deal to buy Seagen.
2023-12-01 09:01:31 - Zacks Investment Research
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.
2023-11-05 10:00:00 - InvestorPlace
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross' Tongue
Bill Gross, the eponymous Bond King, is wading into the stock market to advise investors. Worryingly, he pointed to an imminent fourth-quarter recession closing out 2023.
2023-11-02 10:00:00 - The Motley Fool
This High-Yield Dividend Stock Is a Proven Wealth Creator
In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has been among the group's worst performers this year.
2023-11-01 12:11:14 - Proactive Investors
Seagen 3Q revenue beat driven by jump in product sales
Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimates. The cancer-focused biotechnology company which is being acquired by Pfizer reported revenue of $649 million for 3Q.